您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Adezmapimod
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Adezmapimod
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Adezmapimod图片
CAS NO:152121-47-6
包装与价格:
包装价格(元)
10 mM * 1 mL in DMSO电议
10mg电议
50mg电议
100mg电议
200mg电议
500mg电议
1 g电议

产品名称
SB 203580
RWJ 64809
产品介绍
Adezmapimod (SB 203580) 是一种选择性的,ATP 竞争性的p38 MAPK抑制剂,对SAPK2a/p38SAPK2b/p38β2IC50分别为 50 nM 和 500 nM。Adezmapimod 抑制 LCK,GSK3β 和 PKBα,IC50比 SAPK2a/p38 高 100-500 倍。Adezmapimod 不抑制 JNK 活性,是一种自噬 (autophagy) 和线粒体自噬 (mitophagy) 激活剂。
生物活性

Adezmapimod (SB 203580) is a selective and ATP-competitivep38 MAPKinhibitor withIC50s of 50 nM and 500 nM forSAPK2a/p38andSAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod does not disruptJNKactivity and is anautophagyandmitophagyactivator[1].

IC50& Target[1]

p38

50 nM (IC50)

p38β2

500 nM (IC50)

体外研究
(In Vitro)

Adezmapimod (SB 203580) (preincubated with 0-30 μM for 1 h and cultured for 24 h in the presence of 20 ng/mL IL-2) prevents the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC50of 3-5 μM[1].
SB203580 blocks PKB phosphorylation (IC503-5 μM). SB203580 inhibitsthe phosphorylation of Ser473 in a dose-dependent manner in both CT6 and activated human T cells and IL-2-responsive BA/F3 F7 B cells[1].

Cell Proliferation Assay[1]

Cell Line:CT6, BA/F3 cell line F7, and PBMC/T cells
Concentration:0-30 μM
Incubation Time:Preincubated with 0-30 μM SB203580 for 1 h and cultured for 24 h in the presence of 20 ng/mL IL-2
Result:Prevented the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC50of 3-5 μM.

Western Blot Analysis[1]

Cell Line:CT6 cells, activated human T cells, and BA/F3 F7 cells
Concentration:0-30 μM
Incubation Time:Preincubated with 0-30 μM SB203580 for 1 h before stimulating with 20 ng/mL IL-2 for 5 min
Result:Inhibited the phosphorylation of PKB at Ser473 in a dose-dependent manner.
体内研究
(In Vivo)

Adezmapimod (SB 203580) (5 mg/kg/day; intra peritoneal injected daily for 16 consecutive days, in female atymic Nu/Nu mice) treatment, p38WT tumors show a significantly smaller tumor burden when compared with p38TM tumors that were treated in parallel[1].

Animal Model:Six-week-old female atymic Nu/Nu mice CAL27 p38WT and p38TM tumors[1]
Dosage:5 mg/kg/day
Administration:Intra peritoneal injected daily for 16 consecutive days
Result:After 2 weeks treatment, CAL27 p38WT tumors were significantly smaller; CAL27 p38TM tumors were not affected by the p38 inhibitor (n=10).
分子量

377.43

性状

Solid

Formula

C21H16FN3OS

CAS 号

152121-47-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder-20°C3 years
4°C2 years
In solvent-80°C6 months
-20°C1 month
溶解性数据
In Vitro: 

DMSO : 20 mg/mL(52.99 mM;ultrasonic and warming and heat to 60℃)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM2.6495 mL13.2475 mL26.4950 mL
5 mM0.5299 mL2.6495 mL5.2990 mL
10 mM0.2649 mL1.3247 mL2.6495 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 0.5%CMC-Na/saline water

    Solubility: 16.67 mg/mL (44.17 mM); Suspended solution; Need ultrasonic

  • 2.

    请依序添加每种溶剂: 5% DMSO    40%PEG300   5%Tween-80   50% saline

    Solubility: ≥ 2.5 mg/mL (6.62 mM); Clear solution

  • 3.

    请依序添加每种溶剂: 10% DMSO    40%PEG300   5%Tween-80   45% saline

    Solubility: 2 mg/mL (5.30 mM); Clear solution; Need ultrasonic

    此方案可获得 2 mg/mL (5.30 mM) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH2O 中,得到澄清透明的生理盐水溶液
  • 4.

    请依序添加每种溶剂: 10% DMSO    90% (20%SBE-β-CDin saline)

    Solubility: 2 mg/mL (5.30 mM); Clear solution; Need ultrasonic

    此方案可获得 2 mg/mL (5.30 mM) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 5.

    请依序添加每种溶剂: 10% DMSO    90%corn oil

    Solubility: 2 mg/mL (5.30 mM); Clear solution; Need ultrasonic

    此方案可获得 2 mg/mL (5.30 mM) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在本网站选购。